Summary
Cohance Lifesciences is investing $18 million in NJ Bio and Aruka Bio to enhance its focus on Antibody-Drug Conjugates (ADC), aiming for deeper integration of NJ Bio's services and focused development of Aruka's proprietary pipeline through potential partnerships, with both transactions funded by internal accruals.